Beijing, China, October 17, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on October 24-26 and virtually on November 2-4, 2022.

Using advanced proprietary gene-editing technologies, Biocytogen has developed five proprietary fully human antibody discovery platforms: RenMab^TM-based monoclonal antibody platform, RenLite^®-based bispecific antibody platform, bispecific ADC platform, TCR-mimic platform and GPCR platform.

With the streamlined antibody development capability, the company has established a diverse preclinical and clinical antibody-based drug pipeline (Figure 1, 2).

Figure 1. Biocytogen’s clinical pipeline in oncology: 2 mAb programs in MRCT phase II and 2 mAbs in phase I

Figure 2. Biocytogen’s preclinical mAbs/BsAb/BsADC pipeline

Dr. Vivian Tian, Sr. Director of Biocytogen Europe Innovation Center (BEIC), will give an oral presentation introducing Biocytogen’s pipeline assets and the progress of Project Integrum highlighting of the progress of several antibody programs, including TNFR2, B7-H3, CCR8, and Siglec-15. During the event, the BEIC BD and Licensing team will be on-site to host a booth (#49), and one-to-one partnering meetings. We are looking forward to discussing licensing and co-development opportunities with you, either on-site or at the virtual conference. Any questions, please contact us at BD-Licensing@biocytogen.com.

Since the launch of Project Integrum, Biocytogen has reached 28 preclinical antibody co-development or licensing agreements with 16 companies, including Merck Healthcare KGaA, RemeGen, China Resources Biopharm, Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) and LiberoThera. Additionally, the company has licensed RenMice^TM (RenMab^TM /RenLite^®) to 16 companies, including Merck Healthcare KGaA, BeiGene, Xencor and Innovent; 33 projects have initiated. With the increasing partnership overseas, Biocytogen is ranked first in the number of domestic collaboration deals in 2022 H1.

Biocytogen’s Contacts

Antibody assets and platforms: BD-Licensing@biocytogen.com

Media: pr@bbctg.com.cn